Industry News
AusBiotech submits on R&D Tax Incentive Discussion Paper
AusBiotech has lodged a submission in response to the ‘Discussion Paper: R&D Tax Incentive Implementation – realising effective Compliance through Guidance and Education’, which was been conducted by AusIndustry to inform development of its guidance agenda. [ + ]
Starpharma stocks rise on positive cancer trial results
Starpharma Holdings (ASX:SPL) shares climbed 12.4% on Wednesday, after the release of positive results from a preclincial study of its dendrimer-docetaxel chemotherapy formulation. [ + ]
Bionomics deal could push cashflow into black
The initial $3m Bionomics has received from its drug development deal with Ironwood Pharmaceuticals could help speed an improvement in cashflow. [ + ]
Middletons acts on $375 million sale of Ascent to Watson Pharmaceuticals
Middletons acted on behalf of the sellers of the Australian and South-East Asian generic pharmaceutical business Ascent Pharmahealth, which was purchased by Watson Pharmaceuticals. [ + ]
Vitamin D testing
Scientists are reporting development of a much-needed reference material to ensure that measurements of vitamin D levels are accurate. [ + ]
US biosecurity board speaks out on H5N1 concerns
The US National Science Advisory Board for Biosecurity has explained in detail its rationale in requesting two papers dealing with highly pathogenic H5N1. [ + ]
Biosceptre develops targeted antibodies for cancer treatment
Biosceptre has announced that it is about to clinically trial the use of targeted antibodies as a method to treat cancer. At a Sydney conference held on 24 January, it was revealed that the company has identified a receptor found only in cancer cells. [ + ]
Immuron, Monash partner to develop colostrum therapy
Melbourne-based Immuron (ASX:IMC) and Monash University will collaborate on products aimed at treating C. difficile infections, using Immuron's colostrum technology. [ + ]
Ascent sold to Watson for $375m
Indian pharmaceutical company Strides Arcolab has sold its Australian generic pharmaceutical manufacturer Ascent Pharmahealth to Watson Pharmaceutical. [ + ]
Mesoblast shares up following FDA tick for phase II trials
The US Food and Drug Administration has given the go-ahead for Mesoblast (ASX:MSB) to conduct phase II trials of its stem cell treatment for Type 2 diabetes. [ + ]
Nominations for PM’s Prizes for Science open
The Prime Minister’s Prizes for Science are now open for nomination, including the $50,000 Science Minister’s Prize for Life Scientist of the Year. [ + ]
Last chance to take part in AusBiotech’s annual CEO survey
With the annual CEO Industry Position Survey 2012 closing this week, AusBiotech urges industry leaders to take this opportunity to contribute to the research, enabling an updated and comprehensive view of the Australian biotechnology sector. [ + ]
Cosmo Bio appoints Australian distributor
Cosmo Bio has appointed United Bioresearch as its Australian distributor. [ + ]
Waters recognises Thomson MS Laboratory as Center of Innovation
Waters Corporation has recognised the Thomson Mass Spectrometry Laboratory at the University of Campinas (UNICAMP), Brazil, as a Waters Center of Innovation. [ + ]
Australian-French partnership team up for drug development
The Monash Institute of Pharmaceutical Sciences and France's Servier have entered a three-year partnership for drug development research into G Protein-Coupled Receptors. [ + ]
